September 8, 2025 – Longevity is now a hot market for a handful of billion-dollar investors according to a recent Wall Street Journal (WSJ) article. We have had our eye on the natural mechanisms of longevity with a year-long collection of stories posted on this same blog over five years ago. Our emphasis is on the infusion of DiTetra Gas, either by individuals breathing directly from the machine or bubbling the Gas into ultra-pure water, called Watt-Ahh. Have healthy lifestyles in the cleanest environment available to trigger our body’s intrinsic longevity finally outpacing the search for either the magical “Fountain-of-Youth Drug” or organ transplant surgeries? Sadly, the majority of the new multi-billion research studies identified in the WSJ longevity article seem to be a continuation of traditional medicine with Artificial Intelligence (AI) influences. Anyway, the ultra-rich and those in international dictator power may be the only ones who can afford organ transplants to be able to live to the mythical 150 years old.
Longevity – “Pushing Once Something of an Academic Backwater into the Cultural Mainstream”
I thought the quote from the WSJ article in the subtitle above does not give deserved credit to the holistic health movement that is awakening in this Country. The article also further states that many companies have failed in the past* but there is a huge infusion of investment monies to support new science with the speculation of eventually going mainstream this time. The high-stakes gamble include 1) develop drugs to rejuvenate and reprogram aging cells using AI, 2) develop drugs to treat diseases of aging, 3) test trials on new obesity drugs, and of course, the most sensible to us with the least side effects are: 4) lab tests (including health tracking devices) and lifestyle recommendations. What is interesting is the WSJ article mentions aging-organ transplants but does not identify any major investment in that field by the ultrawealthy longevity investors.
What is a “Longevity Company”?
The WSJ article states … “There is no consensus on what makes something a longevity company. The Journal identified three key areas the ultrawealthy are focused on, by companies’ publicly reported missions: Efforts to reverse or change aging, develop treatments for age-related diseases, or sell products or services claiming to improve health and extend lifespan.” For the latter, our Technology is right in the sweet spot.
* As a failure example given in the WSJ article, Unity Biotechnology raised $355 million since 2013 to develop medicines targeting cells linked to aging. The company was recently delisted from the Nasdaq and announced plans in June of 2025 to dissolve.